Tumour Driver Discovery

Identifies causal molecular drivers of tumour initiation, progression, and treatment resistance. Distinguishes genuine oncogenic drivers from passenger events that co-occur with cancer without causing it – directing therapeutic investment toward targets with mechanistic validation.

Immune Pathway Causation

Resolves the directional biology of dysregulated immune responses in rheumatoid arthritis, lupus, and inflammatory bowel disease. Confirms whether implicated immune genes drive disease or are secondary markers of inflammation.

Risk Factor Mechanism

Maps the pathway from genetic risk variants through regulatory intermediates to clinical endpoints such as lipid levels, plaque formation, or cardiac function -identifying druggable nodes along each causal chain.

CNS Causal Biomarkers

Discovers causal biomarkers for neurodegenerative and psychiatric disorders. The temporal validation layer is particularly valuable in neurology, where disease progression follows defined biological trajectories that constrain causal ordering.

Mechanism Elucidation

Establishes causal mechanisms where cohorts are inherently small. Multi-evidence validation provides confidence through convergence – combining genetic, perturbation, and prior knowledge evidence to validate causal claims in data-limited settings.

Causal Pathway Overlap

Identifies causal pathways shared across indications. Where existing drugs target causal genes in one disease, BiRAGAS determines whether the same causal pathway is operative in a second indication – supporting expedited repurposing programmes.

Target Identification

Generate a prioritised, causally validated target list with tiered confidence classifications – directing early-stage investment toward genes with the strongest mechanistic evidence.

Target Validation

Test whether a nominated target is causally upstream of a disease endpoint. Produce an evidence dossier suitable for internal review boards or external partnership due diligence.

Patient Stratification

Identify causal subgroups within a patient population where distinct causal mechanisms are operative – revealing which segments are most likely to respond to a given targeted intervention.

Regulatory Evidence

Generate mechanistic evidence packages addressing FDA requirements for causal demonstration. Full provenance tracking and evidence grading support regulatory submission workflows.

Biomarker Discovery

Identify causal biomarkers for patient selection, disease monitoring, and treatment response prediction – grounded in validated causal relationships rather than correlative signatures.

Combination Strategy

Use comparative and counterfactual workflows to identify causal pathway interactions — informing rational combination strategies where single-target approaches are insufficient.